AnGes Inc
OTC:AMGXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Thermador Groupe SA
PAR:THEP
|
FR |
|
H
|
Hainan Manaslu Acquisition Corp
NASDAQ:ABLV
|
CN |
|
Claros Mortgage Trust Inc
NYSE:CMTG
|
US |
|
A
|
AgileThought Inc
OTC:AGILQ
|
US |
|
Philly Shipyard ASA
OTC:AKRRF
|
US |
|
C
|
Carelabs Co Ltd
KOSDAQ:263700
|
KR |
|
R
|
Refine Group AB (publ)
STO:REFINE
|
SE |
|
H
|
Hoang Anh Gia Lai Agricultural JSC
VN:HNG
|
VN |
|
C
|
Carrefour SA
OTC:CRERF
|
FR |
|
Huida Sanitary Ware Co Ltd
SSE:603385
|
CN |
|
PolyPid Ltd
NASDAQ:PYPD
|
IL |
|
Elica SpA
MIL:ELC
|
IT |
|
A
|
Alper Consultoria e Corretora de Seguros SA
BOVESPA:APER3
|
BR |
|
Afentra PLC
LSE:AET
|
UK |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
AnGes Inc
TSE:4563
|
22.6B JPY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
376.8B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
AnGes Inc
Glance View
AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for AnGes Inc is -597.8%, which is above its 3-year median of -5 814.1%.
Over the last 3 years, AnGes Inc’s Net Margin has increased from -21 942.4% to -597.8%. During this period, it reached a low of -21 942.4% on Dec 31, 2022 and a high of -597.8% on Jan 1, 2026.
